Functional effects of levosimendan in rat basilar arteries in vitro

Current Neurovascular Research

Volumn 10, Issue 2, 2013, Pages 126-133

  Konczalla, Juergen ^a   Mrosek, Jan ^a   Wanderer, Stefan ^a   Schuss, Patrick ^a   Güresir, Erdem ^a   Seifert, Volker ^a   Vatter, Hartmut ^a   Platz, Johannes ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Endothelin; ET(A) receptor; ET(B) receptor; ET 1; Levosimendan; Prostaglandin

Indexed keywords

ACETYLCHOLINE; CYCLIC GMP; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; LEVOSIMENDAN; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PROSTAGLANDIN F2 ALPHA; SARAFOTOXIN S6C;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTERY TONE; ARTICLE; BASILAR ARTERY; BLOOD VESSEL REACTIVITY; BRAIN ARTERY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 84879822180     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202611310020005     Document Type: Article

References (32)

1. Archan S, Toller W. Levosimendan: current status and future prospects. Curr Opin Anaesthesiol 2008; 21(1): 78-84.
2. Figgitt DP, Gillies PS, Goa KL. Levosimendan. Drugs 2001;61(5):613-27.
3. Montes FR, Echeverri D, Buitrago L, et al. The vasodilatory effects of levosimendan on the human internal mammary artery. Anesth Analg 2006;103(5):1094-8.
4. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998;31(5):741-9.
5. Roehl AB, Hein M, Loetscher PD, et al. Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury. BMC Neurol 2010;10:97.
6. Roehl AB, Zoremba N, Kipp M, et al. The effects of levosimendan on brain metabolism during initial recovery from global transient ischaemia/hypoxia. BMC Neurol 2012;12(1):81.
7. Cengiz SL, Erdi MF, Tosun M, et al. Beneficial effects of levosimendan on cerebral vasospasm induced by subarachnoid haemorrhage: an experimental study. Brain Inj 2010;24(6):877-85.
8. Busani S, Rinaldi L, Severino C, Cobelli M, Pasetto A, Girardis M. Levosimendan in cardiac failure after subarachnoid hemorrhage. J Trauma 2010;68(5):E108-E110.
9. Lanzino G, Kongable GL, Kassell NF. Electrocardiographic abnormalities after nontraumatic subarachnoid hemorrhage. J Neurosurg Anesthesiol 1994;6(3):156-62.
10. Raabe A, Beck J, Berkefeld J, et al. [Recommendations for the management of patients with aneurysmal subarachnoid hemorrhage]. Zentralbl Neurochir 2005;66(2):79-91.
11. Bederson JB, Connolly ES, Jr., Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 2009;40(3):994-1025.
12. Seifert V, Loffler BM, Zimmermann M, Roux S, Stolke D. Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J Neurosurg 1995;82(1):55-62.
13. Hansen-Schwartz J. Receptor changes in cerebral arteries after subarachnoid haemorrhage. Acta Neurol Scand 2004;109(1):33-44.
14. Vatter H, Konczalla J, Seifert V. Endothelin related pathophysiology in cerebral vasospasm: what happens to the cerebral vessels? Acta Neurochir Suppl 2011;110(Pt 1):177-80.
15. Paczkowska E, Golab-Janowska M, Bajer-Czajkowska A, et al. Increased circulating endothelial progenitor cells in patients with haemorrhagic and ischaemic stroke: The role of Endothelin-1. J Neurol Sci 2013.
16. Larysz-Brysz M, Lewin-Kowalik J, Czuba Z, et al. Interleukin-1beta increases release of endothelin-1 and tumor necrosis factor as well as reactive oxygen species by peripheral leukocytes during experimental subarachnoid hemorrhage. Curr Neurovasc Res 2012;9(3):159-66.
17. Kitazono T, Heistad DD, Faraci FM. Dilatation of the basilar artery in response to selective activation of endothelin B receptors in vivo. J Pharmacol Exp Ther 1995;273(1):1-6.
18. Nilsson T, Cantera L, Adner M, Edvinsson L. Presence of contractile endothelin-A and dilatory endothelin-B receptors in human cerebral arteries. Neurosurgery 1997;40(2):346-51.
19. Schilling L, Feger GI, Ehrenreich H, Wahl M. Endothelin-3-induced relaxation of isolated rat basilar artery is mediated by an endothelial ETB-type endothelin receptor. J Cereb Blood Flow Metab 1995;15(4):699-705.
20. Vatter H, Weidauer S, Konczalla J, et al. Time course in the development of cerebral vasospasm after experimental subarachnoid hemorrhage: clinical and neuroradiological assessment of the rat double hemorrhage model. Neurosurgery 2006;58(6):1190-7.
21. Vatter H, Konczalla J, Weidauer S, et al. Effect of delayed cerebral vasospasm on cerebrovascular endothelin A receptor expression and function. J Neurosurg 2007;107(1):121-7.
22. Konczalla J, Vatter H, Weidauer S, Raabe A, Seifert V. Alteration of the cerebrovascular function of endothelin B receptor after subarachnoidal hemorrhage in the rat Exp Biol Med (Maywood) 2006;231(6):1064-8.
23. Komotar RJ, Zacharia BE, Valhora R, Mocco J, Connolly ES, Jr. Advances in vasospasm treatment and prevention. J Neurol Sci 2007;261(1-2):134-42.
24. Asaeda M, Sakamoto M, Kurosaki M, et al. A non-enzymatic derived arachidonyl peroxide, 8-iso-prostaglandin F2 alpha, in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage participates in the pathogenesis of delayed cerebral vasospasm. Neurosci Lett 2005;373(3):222-5.
25. Trikas A, Antoniades C, Latsios G, et al. Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail 2006;8(8):804-9.
26. Mark KS, Trickler WJ, Miller DW. Tumor necrosis factor-alpha induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells. J Pharmacol Exp Ther 2001;297(3):1051-8.
27. Buyuklu M, Kurum AT, Tatly E, Set T. Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia. Arq Bras Cardiol 2012;99(1):659-64.
28. Jadhav VD, Jabre A, Lee TJ. Effect of phospholipase C blockade on cerebral vasospasm. Cerebrovasc Dis 2008;25(4):362-5.
29. Barnard JW, Ward RA, Taylor AE. Evaluation of prostaglandin F2 alpha and prostacyclin interactions in the isolated perfused rat lung. J Appl Physiol 1992;72(6):2469-74.
30. Seifert V, Stolke D, Kaever V, Dietz H. Arachidonic acid metabolism following aneurysm rupture. Evaluation of cerebrospinal fluid and serum concentration of 6-keto-prostaglandin F1 alpha and thromboxane B2 in patients with subarachnoid hemorrhage. Surg Neurol 1987;27(3):243-52.
31. Koskinen LO, Olivecrona M, Rodling-Wahlstrom M, Naredi S. Prostacyclin treatment normalises the MCA flow velocity in nimodipine-resistant cerebral vasospasm after aneurysmal subarachnoid haemorrhage: a pilot study. Acta Neurochir (Wien) 2009;151(6):595-9.
32. Jensen H, Eija R, Tuomas M, et al. Levosimendan decreases intracranial pressure after hypothermic circulatory arrest in a porcine model. Scand Cardiovasc J 2011;45(5):307-15.